Neurogene Announces Q4 & Full-Year 2024 Results, Updates Neurogene Inc., a clinical-stage company dedicated to developing life-changing genetic medicines for patients and families affected by rare neurological diseases, has announced its fourth quarter and full-year 2024 financial results along with…
J&J Boosts U.S. Investment to $55B Over Four Years Johnson & Johnson, one of the world’s leading healthcare and pharmaceutical companies, has announced a significant increase in its investment in the United States. Over the next four years, the company…
Johnson & Johnson to Build Advanced Biologics Facility in North Carolina Johnson & Johnson (the “Company”) is set to break ground on a new, cutting-edge biologics manufacturing facility in Wilson, North Carolina. The 500,000-square-foot facility represents a significant expansion of…
AstraZeneca to Invest $2.5B in Beijing R&D, Biotech & Manufacturing AstraZeneca has announced a major investment of $2.5 billion in Beijing to establish its sixth global strategic R&D centre, alongside significant research and manufacturing agreements aimed at accelerating life sciences…
Novartis’ Fabhalta® (iptacopan) Wins Third FDA Approval for C3G Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta® (iptacopan) for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria. This milestone makes…
FDA Approves Alnylam’s AMVUTTRA® for ATTR-CM Treatment Alnylam Pharmaceuticals, Inc., a pioneer in RNAi therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for its RNAi-based therapeutic, AMVUTTRA® (vutrisiran). This…
Optum Rx to Modernize Pharmacy Payment Models Rising drug prices set by pharmaceutical manufacturers are placing significant financial strain on pharmacies across the United States. As the cost of prescription drugs increases, many pharmacies struggle to maintain high-quality patient care.…
MiNA Therapeutics Adds Norbert Bischofberger to Board, Bríd Ryan as CSO MiNA Therapeutics Limited, a leader in the development of small activating RNA (RNAa) therapeutics, has announced key leadership changes to strengthen its scientific and strategic capabilities. The company has…
Shift Bioscience Strengthens Leadership Team to Accelerate Rejuvenation Therapeutics Development Shift Bioscience, a pioneering biotechnology company utilizing an AI-powered virtual cell platform to combat age-related diseases, has announced the strategic appointments of Jill Reckless, Ph.D., as Translation Advisor, and Laurence…
InTandem Capital Invests in Clinilabs InTandem Capital Partners (“InTandem Capital” or the “Firm”), a private equity firm specializing in healthcare services, has officially announced its strategic partnership with Clinilabs (the “Company”). Clinilabs is a global, full-service contract research organization (CRO)…
Seismic Therapeutic Starts Phase 1 Trial of S-1117 for Antibody-Mediated Diseases Seismic Therapeutic, Inc., a machine learning-driven immunology company, has announced a significant milestone in its journey toward developing transformative therapies for autoimmune diseases. The company has dosed the first…
Noramco Group Invests $25M in Halo Pharma for Sterile Injectables The Noramco Group Invests $25 Million in Halo Pharma’s Whippany Facility to Establish Sterile Injectable Manufacturing The Noramco Group, a fully integrated North American-based supplier of active pharmaceutical ingredients (APIs)…